Rhythm Pharmaceuticals, Inc.’s setmelanotide has lost its accelerated assessment status at the European Medicines Agency, meaning the marketing authorization application (MAA) for the potential treatment of two rare genetic disorders of obesity is now being reviewed under standard timelines. The company has not given an explanation for the change.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?